18:17 , Jan 11, 2019 |  BC Week In Review  |  Company News

Regeneron, Sanofi narrow focus of immuno-oncology deal

By narrowing the focus of a 2015 immuno-oncology deal, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) gains more freedom to play in its combinations sandbox as partner Sanofi (Euronext:SAN; NASDAQ:SNY) turns to other immuno-oncology agents in its pipeline....
00:11 , Jan 8, 2019 |  BC Extra  |  Company News

Regeneron, Sanofi narrow focus of immuno-oncology deal

By narrowing the focus of a 2015 immuno-oncology deal, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) gains more freedom to play in its combinations sandbox as partner Sanofi (Euronext:SAN; NASDAQ:SNY) turns to other immuno-oncology agents in its pipeline....
04:19 , Jan 4, 2019 |  BC Week In Review  |  Financial News

TCR2 seeks IPO as first program slated to enter clinic

Looking to bring at least one of its cell therapy programs to the clinic in 2019, TCR2 Therapeutics Inc. (Cambridge, Mass.) filed on Dec. 28 to raise $100 million in an IPO on NASDAQ. TCR2...
13:43 , Jan 3, 2019 |  BC Innovations  |  Distillery Therapeutics

Pulmonary

INDICATION: Pulmonary fibrosis Patient sample and mouse studies suggest inhibiting MUC5B polymerization could help treat pulmonary fibrosis. In lung samples from IPF patients, epithelial cell levels of MUC5B, which forms polymeric gels in alveoli, and...
22:56 , Dec 28, 2018 |  BC Extra  |  Financial News

TCR2 seeks IPO as first program slated to enter clinic

Looking to bring at least one of its cell therapy programs to the clinic next year, TCR2 Therapeutics Inc. (Cambridge, Mass.) filed on Friday to raise $100 million in an IPO on NASDAQ. TCR2 is...
04:20 , Dec 21, 2018 |  BC Innovations  |  Product R&D

Cell therapies seek solid ground

To make cell therapies work in solid tumors, drug companies will have to either master combination therapies or figure out how to make their treatments trigger broad immune responses that extend beyond the antigen specificity...
23:59 , Dec 11, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Mouse studies suggest a vaccine based on a tetanus toxoid-MUC1 conjugate could help treat MUC1-expressing breast cancer. The conjugate consists of a 22-mer human MUC1 peptide conjugated to tetanus toxoid carrier protein,...
22:36 , Dec 7, 2018 |  BioCentury  |  Finance

Taking Tesaro

While the $5.1 billion takeout price for Tesaro Inc. (NASDAQ:TSRO) is a far cry from its $9.8 billion peak valuation, investors who spoke with BioCentury see the final price tag as a fair value. GlaxoSmithKline...
18:04 , Dec 7, 2018 |  BC Week In Review  |  Company News

GSK gains Zejula, immuno-oncology portfolio in $5.1B Tesaro takeout

Although it's inheriting a portfolio of cancer compounds from Tesaro Inc. (NASDAQ:TSRO) that fall squarely into competitive areas, GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) expects to transform the candidates, including Zejula niraparib, into best-in-class therapies under Hal...
00:50 , Dec 4, 2018 |  BC Extra  |  Company News

GSK gains Zejula, immuno-oncology pipeline in $5.1B Tesaro acquisition

Although it's inheriting a portfolio of cancer compounds from Tesaro Inc. (NASDAQ:TSRO) that fall squarely into competitive areas, GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) expects to transform the candidates, including Zejula niraparib, into best-in-class therapies under Hal...